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Abstract
 
Neutrophil apoptosis occurs both in the bloodstream and in the tissue and is considered essential
for the resolution of an inflammatory process. Here, we show that p38–mitogen-activated protein
kinase (MAPK) associates to caspase-8 and caspase-3 during neutrophil apoptosis and that p38-
MAPK activity, previously shown to be a survival signal in these primary cells, correlates with
the levels of caspase-8 and caspase-3 phosphorylation. In in vitro experiments, immunoprecip-
itated active p38-MAPK phosphorylated and inhibited the activity of the active p20 subunits of
caspase-8 and caspase-3. Phosphopeptide mapping revealed that these phosphorylations occurred
on serine-364 and serine-150, respectively. Introduction of mutated (S150A), but not wild-type,
TAT-tagged caspase-3 into primary neutrophils made the Fas-induced apoptotic response
insensitive to p38-MAPK inhibition. Consequently, p38-MAPK can directly phosphorylate
and inhibit the activities of caspase-8 and caspase-3 and thereby hinder neutrophil apoptosis,
and, in so doing, regulate the inflammatory response.
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Introduction
 
Mature neutrophils are released from the bone marrow to
the bloodstream (1), and from there they are recruited to
inflamed foci by cytokines and chemoattractants. In the
bloodstream, and even more extensively in the tissues, aging
neutrophils are effectively eliminated by apoptosis (2, 3).
Therefore, the induction and control of such cell death are
considered to be essential factors in the resolution or pro-
gression of an inflammatory response. Knowledge of the
signaling mechanisms that regulate neutrophil apoptosis is
insufficient, partly due to methodological limitations; the
short life span of neutrophils rules out transfection, and
microinjection of neutrophils is not feasible (4).
Caspases are major executors of the apoptotic program in
most cell types, including human neutrophils. The initiation
of the caspase cascade is often triggered by activation of a
death receptor, such as trimerization of the Fas receptor.
An active Fas receptor recruits the proteins necessary to
start the caspase cascade by catalyzing the processing of
procaspase-8 to its active form, the caspase-8 heterodimer,
composed of a p20 and a p12 subunit (5). Similar down-
stream enzymatic activation events have been described for
all procaspases. Regarding regulation of active caspases, direct
interactions with different cellular lipids and proteins have
been implicated (6, 7). In the present search for a mechanism
whereby p38–mitogen-activated protein kinase (MAPK)
can signal survival in neutrophils, it is particularly interesting
that a few works have indicated that biochemical modifica-
tions can impair caspase activities. First, it has been shown
that procaspase-3 and caspase-3 can be nitrosylated and that
this results in impaired processing and inactivation in human
cell lines (8). Second, active Akt was demonstrated to phos-
phorylate and impair the processing of human procaspase-9
and also to phosphorylate (Ser-196) and inactivate human
caspase-9 in different transfected cell lines (9). However,
this amino acid residue is not found in mice procaspase-9
(10). More importantly, during Fas-induced apoptosis of
neutrophils, no activation of Akt can be detected (11).
Recently, p42/p44-MAPK has also been shown to phos-
phorylate a conserved residue (Thr-125) in caspase-9 and
to decrease its activity in mammalian cell extracts (12).
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However, inhibition of p42/p44-MAPK has no effect on
spontaneous and Fas-induced neutrophil apoptosis (11, 13).
Despite these findings and the fact that p38-MAPK appears
to play a crucial role in regulating survival in many cell
types (14–17), no information on its mechanisms of action
is available.
The constitutive p38-MAPK activity, found by us and
others in freshly isolated neutrophils (11, 18), is most
probably caused by factors present in the blood, and con-
sequently the subsequent decrease in this MAPK activity
(11) can be explained by such factors being washed away
during the isolation of these cells. Inactivation of constitu-
tive p38-MAPK activity and Fas-induced activation of
caspase-3 occur concurrently, suggesting that neutrophil
apoptosis is initiated by, and dependent on, such inactiva-
tion of p38-MAPK (11). The fact that the later reappear-
ance of p38-MAPK activity in isolated neutrophils is pre-
ceded by a rise in caspase-3 activity (11) suggests that it
could constitute an apoptosis-induced negative feedback
mechanism of this process in a manner similar to that
noted for Akt (19).
 
Materials and Methods
 
Cells and Evaluations.
 
Human neutrophils were isolated and
maintained as described previously (11). Fas receptors were en-
gaged by incubating the cells with an anti-Fas monoclonal Ab
(CH-11, 150 ng/ml; Immunotech). All data are expressed as
mean 
 
 
 
 SD (
 
n
 
 
 
 
 
 6) or SEM (
 
n
 
 
 
 
 
 6), and statistical significance of
the differences was analyzed by paired Student’s 
 
t
 
 test: 
 
*
 
, P 
 
 
 
 0.05,
 
**
 
, P 
 
 
 
 0.01.
 
Immunoprecipitations and Western Blot Analysis.
 
Neutrophils
were lysed, and cell debris was removed by centrifugation, as
described previously (11). The remaining supernatant was
precleared with protein-G plus agarose (Oncogene Research
Products). Thereafter, 40 
 
 
 
l agarose conjugated with an anti-
phospho–p38-MAPK (Thr180/Tyr182) IgG1 mAb (New En-
gland BioLabs, Inc.), an anti–p38-MAPK IgG mAb (Santa Cruz
Biotechnology, Inc.), or, as controls, with anti–c-Myc IgG1 mAb
(ClONTECH Laboratories, Inc.), anti-Fyn IgG1 Ab, or nonim-
mune anti–rabbit IgG (Santa Cruz Biotechnology, Inc.) were
added to the samples. The samples were incubated under rotation
at 4
 
 
 
C overnight. Alternatively, 20 
 
 
 
l agarose, conjugated with
an anti–caspase-3 polyclonal IgG Ab (Santa Cruz Biotechnology,
Inc.) was added to the samples, which were incubated as afore-
mentioned for 2 h. The immunoprecipitates were washed four
times with lysis buffer and these, or lysates of intact cells, were
boiled in sample buffer (11), after which the proteins were sepa-
rated by SDS-PAGE and electrophoretically transferred to nitro-
cellulose membranes. It is worth mentioning that in the anti–cas-
pase-3 immunoprecipitates, we observed a low recovery of the
active p20 kD of the caspases (Fig. 2). A possible explanation for
this finding is a much larger abundance of procaspases resulting in
a preferential immunoprecipitation of these proforms. The mem-
branes were analyzed with an anti–caspase-8 polyclonal Ab
(Chemicon or Santa Cruz Biotechnology, Inc.), an anti–caspase-3
polyclonal IgG Ab (BD Biosciences or Santa Cruz Biotechnol-
ogy, Inc.), an anti-p38 MAPK
 
 
 
 IgG Ab, a MAPK
 
 
 
 IgG mAb, or
an HA IgG
 
2a
 
 mAb (F-7) (Santa Cruz Biotechnology, Inc.), an
anti–caspase-9 polyclonal IgG Ab (BD Biosciences), an anti–
phospho-p38 MAPK (Thr180/Tyr182) IgG1 mAb (New En-
 
gland BioLabs, Inc.), or the anti–phospho-serine IgM
 
 
 
 mAb
16B4 (BIOMOL Research Laboratories, Inc.). Before immuno-
blotting, the membranes that contained radioactive labels were
analyzed using a PhosphorImager. As indicated in the figure leg-
ends, certain blots were stripped and reprobed according to the
instructions of the manufacturers.
 
Expression of Human Caspases-8, Caspase-3, and Hamster Cas-
pase-3.
 
The pET21b vectors containing COOH-terminally
His
 
6
 
-tagged human procaspase-8 or procaspase-3 (20, 21) were
provided by E.S. Alnemri (Kimmel Cancer Institute, Philadel-
phia, PA). The pET15b vector containing COOH-terminally
His
 
6
 
-tagged hamster procaspase-3 (22) was provided by X. Wang
(University of Texas Southwestern Medical Center, Dallas, TX).
Exponentially growing 
 
Escherichia coli
 
 BL21(DE3)pLysS (Novagen)
carrying the expression plasmids were induced at 30
 
 
 
C with 1
mM isopropyl-1-thio-
 
 
 
-
 
d
 
-galactopyranoside (IPTG) and al-
lowed to produce the procaspases for 1 h (23). Thereafter, the
proteins were purified under native conditions using a Ni
 
2
 
 
 
 affin-
ity resin according to the instructions of the manufacturer
(QIAGEN). Procaspase-8 and procaspase-3 were activated by
preincubation for 15 min at 37
 
 
 
C.
 
Fluorometric Assays for Caspase Activities.
 
Ile-Glu-Thr-Asp
(IETD)–aminomethylcoumarin (AMC; Upstate Biotechnology)
and Asp-Glu-Val-Asp (DEVD)–AMC (Upstate Biotechnology),
which are fluorogenic substrates for caspase-8 and caspase-3, re-
spectively, were added to cell lysates, and the activities of the cas-
pases (cleavage of AMC) were measured separately as described
previously (11). The activities of recombinant human caspase-6
(Calbiochem), caspase-8, caspase-3, or Chinese hamster caspase-3
were assayed in caspase buffer (50 mM Tris, pH 8.0, 0.5 mM
EDTA, 0.5 mM sucrose, 5% glycerol, and 10 mM DTT) supple-
mented with 20 
 
 
 
l of agarose-conjugated anti–active-phospho–
p38-MAPK immunoprecipitate (from freshly isolated neutro-
phils) or, as controls, 20 
 
 
 
l of agarose-conjugated anti-cMyc or
anti-Fyn (agarose conjugated) immunoprecipitate.
 
32
 
P-Phosphorylation of the Caspases In Vivo.
 
5 
 
 
 
 10
 
7
 
 neutro-
phils/ml were preincubated for 2 h in a calcium- and phosphate-
free medium (136 mM NaCl, 5.9 mM KCl, 1.2 mM MgSO
 
4
 
, 5.0
mM NaHCO
 
3
 
, 5.5 mM glucose, and 20 mM HEPES, pH 7.4)
supplemented with 2 mCi/ml [
 
32
 
P]orthophosphate; some cells
were also exposed to 20 
 
 
 
M of SB203580 during the last 10 min
of this incubation. Thereafter, the cells were washed and resus-
pended in RPMI 1640 supplemented with 5% FCS and stimu-
lated with the anti-Fas monoclonal Ab for 4 h in the absence or
presence of 20 
 
 
 
M of SB203580. Caspases were subsequently
immunoprecipitated as aforementioned, using agarose-conju-
gated anti–caspase-3 polyclonal Ab.
 
Evaluation of Secondary Necrosis by Flow Cytometry.
 
The cells
were incubated for 12 h in multi-well cell culture plates at 37
 
 
 
C in
a humidified 5% CO
 
2
 
–95% air environment before studies of early
and late apoptosis were performed by flow cytometry as described
previously (11). In brief, to distinguish early from late apoptosis
(secondary necrosis), the cells were stained simultaneously with
FITC-conjugated annexin V and propidium iodide. The former
binds to phosphatidylserine on the surface of both early and late ap-
optotic cells, whereas the latter stains cells that have lost their
plasma membrane integrity, as is the case for late apoptotic cells.
 
p38-MAPK Phosphorylation Assay.
 
The p38-MAPK phos-
phorylation assay was initiated by adding 10 
 
 
 
Ci 
 
 
 
-[
 
32
 
P]ATP
(ICN Biomedicals) and 1 
 
 
 
g of substrate, that is, recombinant
human caspase-8, caspase-3 or hamster caspase-3, BSA, or a puri-
fied extract from 
 
E. coli
 
 containing the empty vector in a reaction
buffer (25 mM Tris, pH 7.5, 5 mM 
 
 
 
-glycerophosphate, 0.1 mM 
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Na
 
3
 
VO
 
4
 
 and 10 mM MgCl
 
2
 
) (11). The incubations with recom-
binant caspase-8 and caspase-3 were performed with or without
20 
 
 
 
M of SB203580 (Calbiochem). The effects of phosphoryla-
tion on caspase activities were assessed in the absence or presence
of 10 mM cold ATP and substrate (i.e., active recombinant hu-
man caspase-8, caspase-3, caspase-6, hamster caspase-3, or BSA/
extracts from bacteria containing an empty vector as controls).
The assays were run for 60 min at 30
 
 
 
C. Thereafter, the degrees
of phosphorylation were analyzed by autoradiography, and the
activities of the two caspases were measured as aforementioned.
 
Immunoprecipitation of Active and Inactive Fas and Cleavage of Pro-
caspase-8 In Vitro.
 
Immunoprecipitation of the active Fas recep-
tor was performed as described previously (24). In brief, 5 
 
 
 
 10
 
7
 
neutrophils/ml were incubated with 2 
 
 
 
g/ml anti–APO-1 anti-
body (Bender MedSystems) for 5 min at 37
 
 
 
C, or the antibody
was added after the cells were lysed (controls). Active receptor
trimers or single inactive receptors (controls) were subsequently
precipitated for 2 h with protein A–Sepharose (Amersham Bio-
sciences), after which the beads were washed and resuspended in
25 
 
 
 
l of double-concentrated reaction buffer (25). These samples
were added to 25 
 
 
 
l of the aforementioned p38-MAPK phos-
phorylation assay buffer containing 500 ng of procaspase-8 and
the immunoprecipitates obtained using 20 
 
 
 
l of agarose-conju-
gated antibody against active p38-MAPK or an isotype-matched
control antibody. These mixtures were incubated for 24 h at 4
 
 
 
C,
and the samples were subsequently immunoblotted for caspase-8.
 
Assaying Procaspase-3 Cleavage In Vitro.
 
The assay was initi-
ated by mixing 200 ng of active recombinant caspase-8 suspended
in 25 
 
 
 
l of the previously described caspase buffer (double con-
centrated) with 25 
 
 
 
l of the aforementioned p38-MAPK phos-
phorylation assay buffer containing 300 ng of procaspase-3 and
immunoprecipitates obtained using 20 
 
 
 
l of agarose-conjugated
antibody against active p38-MAPK or an isotype-matched control
antibody. The assay mixture was incubated for 35 min at 37
 
 
 
C, af-
ter which the samples were immunoblotted for caspase-3.
 
Tryptic Phosphopeptide Mapping and Phosphoamino Acid Analysis.
 
The radioactively labeled bands, corresponding to either caspase-8
or caspase-3, were localized by exposure on a PhosphorImager,
excised from nitrocellulose filters and digested in situ with trypsin
(modified sequencing grade; Promega) followed by two-dimen-
sional phosphopeptide mapping, essentially as described by
Blume-Jensen et al. (26). After exposure on a PhosphorImager,
phosphopeptides were eluted from the plates in pH 1.9 buffer
(formic acid/glacial acetic acid/double-distilled water; 44:156:
1800, vol/vol/vol) and lyophilized. The fractions were subjected
to two-dimensional phosphoamino acid analysis and automated
Edman degradation in parallel. For Edman degradation, phospho-
peptides were coupled to Sequelon-AA membranes (Millipore)
according to the manufacturer’s instructions and sequenced on a
gas phase sequencer (model 470A; Applied Biosystems). The ra-
dioactivity in released phenylthiohydantoin derivatives from each
cycle was quantitated by exposure on a PhosphorImager.
 
Plasmid Constructs and Site-directed Mutagenesis.
 
Human cas-
pase-3 was amplified from the pET21b vector (provided by E.S.
Alnemri) using the following primers: 5
 
 
 
-GCGGGTACCATG-
GAGAACACTGAAAACTCA-3
 
 
 
 and 5
 
 
 
-CGCGCATGCT-
TAGTGATAAAAATAGAGTTC-3
 
 
 
. The PCR fragment of
caspase-3 was subcloned inframe into the KpnI/SphI sites of the
bacterial expression vector pTAT-HA, provided by S. Dowdy
(Howard Hughes Medical Institute, La Jolla, CA) (27, 28). To
replace the single serine residue in caspase-3 with an alanine res-
idue, we used the in vitro Quikchange™ site-directed mu-
tagenesis kit (Stratagene) as indicated by the manufacturers and
 
the oligonucleotide 5
 
 
 
-GAGGGGATCGTTGTAGAGCCCT-
AACTGGAAAACCC-3
 
 
 
 (the mutated bases Ser-150–Ala are
underlined). The mutation was verified by sequence analysis.
 
Preparation and Use of TAT Fusion Proteins. E.  coli
 
 BL21-
(DE3)pLysS (Novagen) carrying the expression vector pTAT-
HA-procaspase-3 was incubated at 37
 
 
 
C with 0.2 mM IPTG
overnight. Additional IPTG was added to the bacteria (final con-
centration 
 
 
 
 0.450 mM) when the bacteria had reached OD
 
600
 
 of
0.6. The bacteria were allowed to further produce the vector pro-
Figure 1. Caspase-8 and caspase-3 are coimmunoprecipitated with
p38-MAPK. Neutrophils were incubated with anti-Fas Ab for the indicated
times and lysed. (A) Samples were immunoprecipitated with an anti–p38-
MAPK  or an isotype-matched control (C) antibody and subsequently
assessed by Western blotting. The blots were either analyzed with a mixture
of two antibodies respectively directed against caspase-8 (both the proform,
pC8, and the active form, C8) and caspase-3 (both the proform, pC3, and
the active form, C3), sequentially stripped, and reprobed with antibodies
against p38-MAPK  (p38 ). (B) Samples were immunoprecipitated with
an anti-phospho–p38-MAPK or an isotype-matched control (C) antibody
and subsequently assessed by Western blotting. The blots were sequentially
analyzed with the antibodies against caspase-8, caspase-3, phospho–p38-
MAPK (P-p38), p38-MAPK  (p38 ), and p38-MAPK  (p38 ). The
blots in A and B are representative of at least seven separate experiments. 
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tein for an additional 2 h period. Thereafter, the proteins were puri-
fied under either native (as aforementioned for in vitro assays) or de-
naturing conditions (urea, for introduction to intact cells) using a
Ni
 
2
 
 
 
 affinity resin according to the instructions of the manufacturer
(QIAGEN). The preparation of procaspase-3 was desalted using
chromatography columns (Micro Bio-Spin; Bio-Rad Laboratories).
2.5 
 
 
 
 10
 
5
 
 cell were preincubated with 150 nM of either the wild-
type TAT-HA-procaspase-3 or its mutant for 1 h (30 min on ice in
the absence of and 30 min at 37
 
 
 
C in the presence of 20 
 
 
 
M of
SB203580) before engagement of the Fas receptor. The uptake of
TAT-tagged proteins was analyzed by Western blot. The cells were
washed three times with PBS and lysed as described previously (11).
To avoid preactivation of neutrophils by possible residual LPS in the
recombinant protein preparations, the cells were incubated in the
presence of 25 
 
 
 
g/ml polymixin B (a specific inhibitor of LPS bio-
activity; reference 29) throughout the experiment.
 
Analysis of Nuclear Morphology.
 
Neutrophils were incubated
for 4 h in multi-well cell culture plates at 37
 
 
 
C in a humidified
5% CO
 
2
 
–95% air environment before being stained with acridine
orange and ethidium bromide as described previously (11) to as-
sess nuclear morphology and cell viability.
 
Results
 
Regulatory Interactions between p38-MAPK and Caspases in
Intact Cells.
 
Initially, we detected procaspase-8 and pro-
caspase-3 (Fig. 1 A), but not procaspase-9 (not depicted), in
immunoprecipitates of total p38
 
 
 
-MAPK, the most abun-
dant p38-MAPK isoform in neutrophils (30). We also spe-
cifically immunoprecipitated active p38-MAPK from anti–
Fas-treated cells, which showed a time-dependent increase
in association of active p38-MAPK with the active p20
subunits of caspase-8 and caspase-3, levels of which were
low or undetectable at time zero (Fig. 1 B). In immuno-
precipitates obtained with an agarose-conjugated, isotype-
matched control antibody, we could not detect any cas-
pase-8 or caspase-3 (Fig. 1, A and B, top two blots). These
findings imply intimate and regulatory interactions be-
tween these caspases and active p38-MAPK.
p38-MAPK activity was initially high and had almost
disappeared after 30 min (Fig. 2 A), whereas caspase-3 ac-
tivity was first detected after 30 min and reached a statisti-
cally significant increase after 1 h (Fig. 2 B), suggesting that
the Fas-induced interactions between active p38-MAPK
and caspases (Fig. 1 B) might require activation of these
proteases. In support of that, the time-dependent increases
in the activities of caspase-8 and caspase-3 (Fig. 2 B) paral-
leled the associations between the active p20 subunits of
these caspases and p38-MAPK (Fig. 1 B). Assuming that
recognition events between MAPKs and interacting sub-
strates are necessary for the specificity of these kinases (31),
our results suggest that active p38-MAPK might have a
regulatory feedback effect on these caspases. We obtained
support for this idea by the finding that inhibition of p38-
Figure 2. p38-MAPK–dependent phosphorylations of
procaspase-8 and procaspase-3 in intact cells. Neutrophils
were incubated with anti-Fas Ab for the indicated times
and lysed. (A) Samples were taken for Western blot analysis
with an anti-phospho–p38-MAPK (P-p38) antibody. The
blot shown is representative of at least eight separate ex-
periments. (B) Alternatively, lysate samples were analyzed
for IETDase (C8) and DEVDase (C3) activities (n   6).
To adjust for differences between blood batches, the caspase
activities measured after 2 h were defined as 100%, and
values at other time points were compared with that level.
Caspase-3 immunoprecipitates were obtained from freshly
isolated or 32P-labeled neutrophils after the indicated periods
of exposure to anti-Fas Ab. (C) Unlabeled neutrophils
were lysed, and the immunoprecipitates were immuno-
blotted with an anti–phospho-serine Ab, stripped, and re-
probed with a mixture of anti–caspase-8 (detecting both
the proform, pC8, and the active form) and anti–caspase-3
(detecting both the proform, pC3, and the active form)
Abs and thereafter with an anti-phospho–p38-MAPK
(P-p38) Ab. (D) The 32P-labeled neutrophils were lysed,
and immunoprecipitates were analyzed by gel electro-
phoresis and blotted. The blots were developed with a
PhosphorImager and subsequently analyzed with a mixture
of the anti–caspase-8 and the anti–caspase-3 Abs, stripped,
and reprobed with the anti-phospho–p38-MAPK Ab. The
blots and the autoradiogram in C and D are representative
of at least three separate experiments.Alvarado-Kristensson et al. 453
MAPK significantly increased the percentage of cells ex-
hibiting secondary necrosis (as revealed by positive propid-
ium iodide staining) during spontaneous and Fas-induced
apoptosis (spontaneous, 7.97   4.6%; spontaneous  
SB203580, 24.8   13.6%; anti-Fas Ab, 10.6   5.5%; and
anti-Fas Ab   SB203580, 31.75   10.4%; n   4).
To evaluate possible p38-MAPK–induced phosphoryla-
tions of caspase-3, we immunoprecipitated this caspase
with a precoupled antibody known to effectively bind this
protein (Fig. 2, C and D). Unfortunately, we were unable
to achieve equally efficient precipitation of caspase-8 with
available anti–caspase-8 antibodies (unpublished data).
However, this problem was partially overcome in our ex-
periments because the anti–caspase-3 antibody also pulled
down readily detectable amounts of caspase-8 (Fig. 2, C
and D). First, we used an unspecific antiphosphoserine an-
tibody to investigate possible phosphorylation events of
caspase-8 and caspase-3 because MAPKs are known to
phosphorylate their substrates on serine residues, and be-
cause this approach enabled analysis of possible caspase
phosphorylations immediately after the cells were isolated.
We observed distinct serine phosphorylations of both pro-
caspase-8 and procaspase-3, which were most prominent
when the p38-MAPK was active, and declined with differ-
ent kinetics after the initial p38-MAPK activity had disap-
peared (Fig. 2 C). In addition, in parallel with the increase
in p38-MAPK activity in whole cell lysates after 4 h (Fig. 2
A), the serine phosphorylations of the caspases also started
to increase after 4 h (Fig. 2 C). Second, we labeled freshly
isolated human neutrophils with 32P for 2 h and, thereafter,
engaged their Fas receptors in the absence or presence of
the p38-MAPK inhibitor SB203580. The time points indi-
cated in Fig. 2 D cannot be compared with those in the
other figures because the illustrated data represent cells that
were preincubated with 32P for 2 h; instead, the caspase
phosphorylations should be related to the evaluation of
p38-MAPK activity in the same experiment (Fig. 2 D).
The observed phosphorylations of the caspases were signif-
icantly ( 60%, as reveal by densitometric analysis), im-
paired by the p38-MAPK inhibitor SB203580 (Fig. 2 D).
SB203580 is known to inhibit the   and   isoforms of
p38-MAPK, but not the   and   isoforms (32). We de-
tected the   and   isoforms in the active p38-MAPK im-
munoprecipitates (Fig. 1 B), which could at least partly
explain why SB203580 does not abolish p38-MAPK–
induced phosphorylation of caspase-8 and caspase-3. How-
ever, at this stage, we cannot exclude that other alternative
mechanisms are also responsible for the observed SB203580-
insensitive phosphorylation of caspase-3. These experi-
ments clearly demonstrate that engagement of Fas causes
substantial  32P-phosphorylation of procaspase-8 and pro-
caspase-3, and that SB203580 can reverse these biochemi-
cal modifications.
p38-MAPK-induced Phosphorylation of Caspase-8 (Ser-364)
and Caspase-3 (Ser-150). We used an in vitro assay to
confirm that caspase-8 and caspase-3 are direct substrates of
p38-MAPK. Active p38-MAPK immunoprecipitated from
freshly isolated neutrophils was incubated with recombi-
Figure 3. p38-MAPK–induced
phosphorylations of caspase-8
and caspase-3 in vitro. (A and
B) Active phosphorylated
p38-MAPK immunoprecipitates
from freshly isolated neutrophils
were incubated with [ -32P]ATP
and recombinant caspase-8 or -3
in the absence or presence of the
p38-MAPK inhibitor SB203580.
As controls, the same reaction
was performed in the absence of
caspases but in the presence of
either purified proteins from E.
coli transformed with an empty
vector (C) or BSA. All blots
were first developed with a
PhosphorImager, cut, and ana-
lyzed with (A) the anti–caspase-8
(pC8 and C8) Ab or (B) the
anti–caspase-3 (pC3 and C3) Ab,
and, lastly, stripped and reprobed
with the anti-phospho–p38-
MAPK (P-p38) Ab. The illus-
trated autoradiograms and blots
are representative of at least seven separate experiments. (C) Active phosphorylated p38-MAPK (P-p38) was immunoprecipitated and incubated with
recombinant caspase-8 and caspase-3 as substrates, in the presence or absence of ATP and under the same conditions as aforementioned. Thereafter, the
activities of caspase-8 and caspase-3 were measured separately. The results are presented as percentage of the activities found in samples incubated in the
same way but with an immunoprecipitate obtained using an isotype-matched control antibody. The data are expressed as mean   SEM of seven separate
experiments. The substrates, recombinant procaspase-8 (pC8) in D and recombinant procaspase-3 (pC3) in E, were incubated in the presence of ATP
and either the immunoprecipitated active phosphorylated p38-MAPK (P-p38) or an immunoprecipitate obtained using an isotype-matched control
antibody (Control). Thereafter, the in vitro amounts of the procaspases (pC8 and pC3) and caspases (C8 and C3), after incubations in the presence of (D)
immunoprecipitated active Fas (FasR; n   3) or (E) active caspase-8 (n   5), were analyzed by Western blotting.Serine Phosphorylation of Caspase-8 and Caspase-3 in Neutrophils 454
nant hamster caspase-3 (not depicted) as well as human cas-
pase-8 or caspase-3 (Fig. 3, A and B) in the presence of
 -[32P]ATP. Both the procaspases and the 20-kD mono-
mers of the active heterodimers of all three caspases were
phosphorylated by the active p38-MAPK in the absence
but not in the presence of SB203580.
Fig. 3 C (based on data obtained using the experimental
conditions indicated in Fig. 3, A and B) shows that the
p38-MAPK–induced phosphorylation of caspase-8 and cas-
pase-3 (ATP present) reduced the enzymatic activities
compared with the unphosphorylated controls (ATP ab-
sent). These results are presented as percentage of the activ-
ities found in control samples incubated with immuno-
precipitates obtained using an isotype-matched control
antibody; no phosphorylation of the caspases was detected
under those conditions (unpublished data). Eliminating
ATP in this assay restored the activities of the two caspases,
even in the presence of active p38-MAPK (Fig. 3 C). The
same effect was observed when human caspase-6 (67.1  
15.2% of control; n   5) or hamster caspase-3 (77.4  
10.2% of control; n   5) were incubated in the presence of
active p38-MAPK (these values are expressed as percentage
of the activities found in samples where ATP was absent).
Thereafter, we investigated whether the p38-MAPK–
induced phosphorylation of procaspase-8 and procaspase-3
affected the handling of these precursor molecules. In in
vivo experiments, procaspase-8 is processed upon recruit-
ment to the active Fas receptor (5); whereas procaspase-3 is
cleaved by active caspase-8. Therefore, we incubated pro-
caspase-8 or procaspase-3 in the absence or presence of ac-
tive p38-MAPK, with the active Fas receptor (Fig. 3 D) or
caspase-8 (Fig. 3 E). This revealed a p38-MAPK–depen-
dent reduction in the levels of caspase-8 (Fig. 3 D) and cas-
pase-3 (Fig. 3 E), and indicated that p38-MAPK–induced
phosphorylation impaired the processing of procaspase-8,
whereas such phosphorylation rendered both caspase-8 and
caspase-3 less stable.
We further examined the phosphorylation of recombi-
nant caspase-8 and caspase-3 by active p38-MAPK immu-
noprecipitates from freshly isolated neutrophils in the pres-
ence of  -[32P]ATP. Phosphorylated procaspase-8 and
procaspase-3 were separated by gel electrophoresis and
transferred to nitrocellulose membranes before tryptic di-
gestion in situ and two-dimensional phosphopeptide map-
ping. As shown in Fig. 4 A, p38-MAPK phosphorylates
caspase-8 on a single peptide fragment, whereas it phos-
phorylates caspase-3 on two peptide fragments. These dif-
ferent phosphopeptides were scraped off the TLC plates
and subjected to two-dimensional phosphoamino acid
analysis. All three phosphopeptides were phosphorylated
on serine residues (Fig. 4 B). The phosphorylated serine
residue in the phosphopeptide that originated from caspase-8
(Fig. 4 A) was located at position 3, as shown by an auto-
mated Edman degradation assay (Fig. 4 C). The phospho-
peptides originating from caspase-3 (Fig. 4 A) had their
phosphoserine residues located either at position 1 (weakest
spot) or 3 (strongest spot) (Fig. 4 C). After compiling all the
theoretical tryptic peptides derived from a complete diges-
tion of procaspase-8 and procaspase-3 and comparing the
possible tryptic peptides with homologous amino acid se-
quences in caspase-6, we concluded that the peptide from
procaspase-8 containing Ser-364 and from procaspase-3
containing Ser-150 were likely to be the phosphorylated
peptides. The peptide derived from procaspase-3, which
contains Ser-150, is proceed by two arginine residues. A
partial tryptic digestion of the arginines will generate two
different phosphopeptides, as we detected in the TLC
plates. Ser-364 and Ser-150 are present in regions that lie
11 amino acids upstream of the active sites of caspase-8 and
caspase-3, respectively (Fig. 5 A). This region, containing
either a Ser or a Thr residue, is conserved among different
human caspases (1, 2, 4, 5, 7, and 9 but not 10 or 14). In
addition, this region is also well conserved among other
vertebrates (for example, caspase-6, -7, -8, -9, and -10
Figure 4. Identification of phosphorylation sites on caspase-8 and
caspase-3. (A) Active phosphorylated p38-MAPK immunoprecipitates
from freshly isolated neutrophils were incubated with [ -32P]ATP and
recombinant procaspase-8 or procaspase-3. The proteins were separated
by SDS–gel electrophoresis, and the separated proteins were digested in
situ with trypsin. The obtained phosphopeptides were separated on cellulose
TLC glass plates (elect.), followed by ascending chromatography
(chrom.). The indicated electrophoresis direction is from the anode to the
cathode. The plates were analyzed in a PhosphorImager as well as exposed
to an X-ray film. (B) The phosphopeptides from caspase-8 or caspase-3
were eluted from the TLC plates and subjected to two-dimensional phos-
phoamino acid analysis. The locations of the phosphoamino acids (top)
were compared with that of phosphoamino acid markers (bottom) as follows:
serine (S), threonine (T), and tyrosine (Y). The phosphopeptides obtained
from A were subjected to amino acid sequencing (C), and the radioactivity
released in each cycle was measured by spotting onto TLC plates and ex-
posure on a Fuji image analyzer. The phosphorylated serine residues, 364
for caspase-8 (C) and 150 for caspase-3 (C), are indicated in the sequence
of the putative fragment from caspase-8 and caspase-3, respectively. The
illustrated phosphomapping is representative of three experiments.Alvarado-Kristensson et al. 455
from Xenopus laevis) and invertebrates (for example, cas-
pase-1 from Drosophila melanogaster). Interestingly, the
three-dimensional structure of this region is also preserved
among caspases (Fig. 5 B), implying a common regulatory
region for caspases that is conserved among species.
Mutated Caspase-3 (S150A) Is Not Regulated by p38-
MAPK. To directly test the role of caspase phosphoryla-
tion in the regulation of apoptosis in intact human neutro-
phils, we subcloned human procaspase-8 and procaspase-3
into TAT-HA vectors. TAT-HA–tagged caspase-8 exhib-
ited no in vitro activity, probably due to a conformational
change, whereas TAT-HA–tagged caspase-3 did. Conse-
quently, we also prepared a TAT-HA–tagged mutated cas-
pase-3 in which serine-150 was replaced with an alanine
residue, and this protein was used together with the wild-
type TAT-HA–tagged caspase-3. Despite overexposure,
we could not detect any phosphorylation of the TAT-
tagged mutated caspase-3 (Fig. 6 A). Furthermore, protease
activity measurements of wild-type TAT-tagged caspase-3
and mutated TAT-tagged caspase-3 (S150A) revealed that,
in contrast to wild type, the activity of the mutated caspase-3
is not modified by the presence of immunoprecipitated ac-
tive p38-MAPK (Fig. 6 B). In vitro experiments revealed
that caspase-3 (S150A) has a lower protease activity than
wild-type caspase-3 (unpublished data). For this reason, and
also to avoid any misinterpretations due to a difference in
the loading of the two TAT-tagged proteins, we studied
the effects of p38-MAPK inhibition (SB203580) on apop-
tosis in primary neutrophils preincubated with either wild-
type or mutated caspase-3. The results show that caspase-3
activity is significantly increased by p38-MAPK inhibition
in nontreated control cells and cells loaded with wild-type
caspase-3, but not mutated caspase-3 (Fig. 6 C). The differ-
ence in protease activity between cells loaded with wild-
type or mutated caspase-3 and incubated with the p38-
MAPK inhibitor SB203580 is even clearer if we subtract
the endogenous caspase-3 activity and express the activities
as percentage of untreated cells (Fig. 6 D). These data
nicely correlate with our findings that p38-MAPK inhibi-
tion (SB203580) increased the percentage of apoptotic cells
(as revealed by acridine orange and ethidium bromide co-
staining) if they were preincubated with wild-type caspase-3,
but not with the mutated caspase-3 (Fig. 6 E). These obser-
vations strongly support the idea that p38-MAPK counter-
acts neutrophil apoptosis by phosphorylation and inactiva-
tion of caspases.
Discussion
We have shown previously (11), as have others (14, 15),
that p38-MAPK constitutes a survival signal in isolated hu-
man and mice granulocytes, and that inactivation of this
protein is a permissive event in spontaneous and Fas-
induced neutrophil apoptosis (11). Furthermore, these pre-
vious findings suggested that active p38-MAPK could signal
survival in primary neutrophils by keeping the activity of the
caspases at low levels. Our initial finding, in the present
work, of a constant association between procaspase-8 and
procaspase-3 and p38-MAPK suggests a mechanism that
could allow p38-MAPK to signal survival because such in-
teraction might enable p38-MAPK–mediated biochemical
modification and regulation of caspase-8 and caspase-3, and
thereby also control of neutrophil apoptosis.
It is known that the proapoptotic stimulus triggered by
an anti-Fas Ab directly recruits procaspase-8 to the Fas re-
ceptor, which facilitates the processing and activation of
this proenzyme and in that way initiates the caspase cas-
cade (5). We noted in the present work that such engage-
ment of Fas receptors on human neutrophils also causes
active p38-MAPK to associate with the active p20 sub-
units of caspase-8 and caspase-3. In addition, our experi-
ments comparing the kinetics of p38-MAPK and caspase-3
revealed an interesting relationship between the activities
of these proteins. In freshly isolated neutrophils, we found
that p38-MAPK was highly active, whereas caspase-3 dis-
played no activity at all and caspase-8 very little. Not until
after 30 min of Fas engagement did caspase-8 and caspase-3
exhibit increased activity, and this pattern coincided
with the absence of p38-MAPK activity. Furthermore, we
have observed previously that this loss of p38-MAPK ac-
tivity does not occur in the presence of the survival factor
GM-CSF (11). These results suggest that the initial deacti-
Figure 5. Ser-364 and Ser-150 are conserved
residues in caspases. (A) The homologous
serine/threonine residue (first box) is found 11
amino acids upstream of the active site (second
box) within the outlined caspases. These residues
are found in the respective, large, p20 subunits
of the caspases. (B) The known three dimensional
structures of the p20 monomers of caspase-8
(34), caspase-3 (35), caspase-9 (36), and caspase-7
(37) are revealed with the three-dimensional
structure viewer Cn3D. In these structures, the
p38-MAPK putative phosphorylation site is
depicted (yellow), below which is the active
site of each caspase.Serine Phosphorylation of Caspase-8 and Caspase-3 in Neutrophils 456
vation of p38-MAPK is essential for Fas-induced stimula-
tion of the caspase cascade in neutrophils. Of interest in
the present context, we noted that p38-MAPK regained
its activity once the caspases showed significantly increased
activities and that inhibition of this activity caused an in-
creased secondary necrosis in neutrophils. Therefore, we
believe that this regain in activity represents a regulatory
feedback mechanism that protects the cells from overacti-
vation of caspases, which would lead to premature second-
ary necrosis and unwanted tissue damage in vivo. Indeed,
such apoptosis-induced feedback has already been demon-
strated for the well-known survival factor Akt (19). A
physical basis for the aforementioned p38-MAPK–medi-
ated regulation of caspase activities is indicated by the fact
that we detected active p20 subunits of caspase-8 and cas-
pase-3 in immunoprecipitates of active p38-MAPK from
Fas-engaged neutrophils. These associations agree with the
notion that p38-MAPK can induce biochemical modifica-
tions of caspase-8 and caspase-3 because such docking of
MAPKs has been suggested to play an important role in
their substrate specificities (31).
To ascertain whether the serine/threonine p38-MAPK
induces phosphorylation of caspase-8 and caspase-3, we
immunoprecipitated these two enzymes and performed
Western blotting to measure if they were phosphorylated
on such residues. We observed distinct serine phosphoryla-
tions of both procaspase-8 and procaspase-3, which were
most prominent in freshly isolated neutrophils (i.e., when
p38-MAPK was active), but declined with different kinet-
ics after the initial p38-MAPK activity had disappeared.
Furthermore, the serine phosphorylations of the caspases
started to increase after 4 h, in parallel with the regain of
p38-MAPK activity. In addition, when we labeled freshly
isolated human neutrophils with 32P for 2 h and engaged
their Fas receptors in the absence or presence of the p38-
MAPK inhibitor SB203580, we found that the caspases
were clearly phosphorylated by a p38-MAPK–dependent
mechanism. Accordingly, the SB203580-induced increase
in caspase-8 and caspase-3 activities in neutrophils under-
going Fas-provoked apoptosis (11) may be due to the
aforementioned observation that active p38-MAPK phos-
phorylates caspase-8 and caspase-3, as in the case of Akt
Figure 6. Mutation of Ser-150 abolishes the effect of
the inhibition of p38-MAPK in vivo. (A) Active phos-
phorylated p38-MAPK immunoprecipitates from freshly
isolated neutrophils were incubated with [ -32P]ATP
and recombinant wild-type TAT–caspase-3 or mutated
TAT–caspase-3 (S150A). The phosphopeptide mapping
was performed as in Fig. 4. The plates were exposed on
a PhosphorImager as well as to film. The indicated
electrophoresis direction is from the anode to the cathode.
(B) Active phosphorylated p38-MAPK (P-p38) was
immunoprecipitated and incubated with recombinant
wild-type TAT–caspase-3 or mutated TAT-caspase-3
(S150A) as substrates in the presence (shaded bars) or
absence (unshaded bars) of ATP. Thereafter, the activities
of TAT–caspase-3 or TAT–caspase-3 (S150A) were
measured separately. The results are presented as per-
centage of the activities found in samples depleted of
ATP. The data are expressed as mean   SD of five
separate experiments. (C) Fas-induced caspase-3 activ-
ity in control cells or cells loaded with TAT–caspase-3
or TAT–caspase-3 (S150A) after 3 h after activation of
the Fas-receptor. Unshaded bars represent cells treated
with 20  M SB203580 (n   4–6). (D) The effect of
SB203580 in cells loaded with TAT-fusion proteins
(n   4). (E) The Fas-treated cells were incubated for
4 h in the presence or absence of TAT-fusion protein
and SB203580 and subsequently stained with acridine
orange and ethidium bromide to assess their nuclear
morphology. The effects are presented as percentage of
untreated control cells (n   4–6). (F) Neutrophils in-
cubated in absence, as control (C) or presence of wild-
type (WT) TAT-caspase-3 or (S150A) mutated (M)
TAT–caspase-3. Samples were taken for Western blot
analysis with an anti–HA-Ab (HA).Alvarado-Kristensson et al. 457
and human caspase-9 in transfected cell lines (9), and that
such phosphorylations lead to inactivation of caspase-8 and
caspase-3. This postulation was confirmed in experiments
in vitro, which clearly showed that caspase-8 and caspase-3
are directly phorphorylated by p38-MAPK on serine-364
and serine-150, respectively, and that these biochemical
modifications significantly reduced their enzymatic activi-
ties. The most straightforward interpretation of our results
is that the p38-MAPK–induced phosphorylations cause ac-
tivity-impairing conformational changes in the caspases. It
also appears as if the observed phosphorylations of pro-
caspase-8 and procaspase-3 affect the processing to the ac-
tive caspases, and that the p38-MAPK–provoked phos-
phorylations of caspase-8 and caspase-3 also result in more
rapid degradation of these two enzymes.
To finally test the aforementioned survival function of
p38-MAPK in primary human neutrophils, we introduced
TAT-tagged wild-type and mutated caspase-3 (S150A).
The results clearly show that the Fas-induced apoptotic re-
sponse in neutrophils containing mutated caspase-3 was not
potentiated upon inhibition of p38-MAPK. The present
data and other results implicating p38-MAPK as both a pos-
itive and a negative regulator of cell survival, depending on
the type of cell studied (33), suggest that the role of p38-
MAPK in a particular cell type is decided by the down-
stream substrates that are phosphorylated by the kinase.
Our results provide a novel and logical explanation for
the mechanism underlying survival signaling by p38-
MAPK in primary neutrophils: the active form of p38-
MAPK associates with caspase-8 and caspase-3, which con-
stitutes the basis for p38-MAPK–induced phosphorylations
on serine-362 and serine-150 of these caspases. These bio-
chemical modifications impair the activities, and possibly
also the stability, of these caspases and thereby weaken their
capacity to induce apoptosis.
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